Research Directions in Genetic Predispositions to Stevens–Johnson Syndrome / Toxic Epidermal Necrolysis

Stevens–Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) is one of the most devastating of adverse drug reactions (ADRs) and was, until recently, essentially unpredictable. With the discovery of several risk alleles for drug‐induced SJS/TEN and the demonstration of effectiveness of screening in reducing incidence, the stage is set for implementation of preventive strategies in populations at risk. Yet much remains to be learned about this potentially fatal complication of commonly used drugs.

[1]  W. Chung,et al.  Pharmacogenomic Advances in the Prediction and Prevention of Cutaneous Idiosyncratic Drug Reactions , 2017, Clinical pharmacology and therapeutics.

[2]  E. Phillips,et al.  Severe Delayed Cutaneous and Systemic Reactions to Drugs: A Global Perspective on the Science and Art of Current Practice. , 2017, The journal of allergy and clinical immunology. In practice.

[3]  M. Mockenhaupt,et al.  Severe Drug Hypersensitivity Reactions: Clinical Pattern, Diagnosis, Etiology and Therapeutic Options. , 2017, Current pharmaceutical design.

[4]  J. Silverberg,et al.  Morbidity and Mortality of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in United States Adults. , 2016, Journal of Investigative Dermatology.

[5]  Melissa A. Basford,et al.  Genetic variation among 82 pharmacogenes: The PGRNseq data from the eMERGE network , 2016, Clinical pharmacology and therapeutics.

[6]  S. Mallal,et al.  Evolving models of the immunopathogenesis of T cell-mediated drug allergy: The role of host, pathogens, and drug response. , 2015, The Journal of allergy and clinical immunology.

[7]  Thachanan Kongpan,et al.  Candidate HLA genes for prediction of co-trimoxazole-induced severe cutaneous reactions , 2015, Pharmacogenetics and genomics.

[8]  M. Nelson,et al.  The International Serious Adverse Events Consortium , 2014, Nature Reviews Drug Discovery.

[9]  M. Schumacher,et al.  A marker for Stevens-Johnson syndrome …: ethnicity matters , 2006, The Pharmacogenomics Journal.

[10]  Yuan-Tsong Chen,et al.  A marker for Stevens–Johnson syndrome , 2004 .

[11]  M. Mockenhaupt,et al.  Epidemiology of erythema exsudativum multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis in Germany (1990-1992): structure and results of a population-based registry. , 1996, Journal of clinical epidemiology.